Valrubicin activates PKCa in keratinocytes: a conceivable mode of action in treating hyper-proliferative skin diseases

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

  • Ina Groenkjaer Laugesen, Denmark
  • Eva Hauge, Denmark
  • Stine Maria Andersen, Denmark
  • Karin Stenderup
  • Elisabeth de Darkó
  • ,
  • Tomas Norman Dam, Denmark
  • Cecilia Rosada, Denmark
Valrubicin is a semisynthetic anthracycline developed as an anti-cancer drug able to ameliorate psoriasis and non-melanoma skin cancer (NMSC) by topical application in animal models. Valrubicin decreases cell proliferation, and induces apoptosis; however its mode of action is still unknown. Valrubicin localizes in the cytoplasm and its valerate moiety resembles diacylglycerol, an activator of protein kinase C (PKC) α, which belongs to the PKC family of cytoplasmic serine/threonine protein kinases. PKCα is observed in the suprabasal layers of normal skin and is associated to keratinocyte growth arrest and differentiation processes. In hyper-proliferative skin diseases the presence of PKCα is altered.
Original languageEnglish
JournalJournal of Drugs in Dermatology
Volume12
Issue10
Pages (from-to)1156-62
Number of pages7
ISSN1545-9616
Publication statusPublished - Oct 2013

See relations at Aarhus University Citationformats

ID: 69536795